Search the Newsreel

MacroGenics 2026: Revenue $32.83M, EPS $0.31— 10-Q Summary

MacroGenics reported strong Q2 2026 results with revenue of $32.83M and diluted EPS of $0.31, largely driven by a TZIELD milestone payment and increased ZYNYZ royalty income. The company achieved net income of $19.52M, a significant improvement from the prior year's loss, following the …

Santacruz Silver Mining Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Santacruz Silver Mining Ltd. Reports Decline In Q2 Bottom Line

(RTTNews) - Santacruz Silver Mining Ltd. (SCZ.V) announced a profit for second quarter that Dropped, from the same period last year The company's bottom line came in at $2.00 million, or $0.02 per share. This compares with $20.97 million, or $0.22 per share, last …

Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?

On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)'s proprietary TRIDENT platform. The decision triggered a $10 million milestone payment to MacroGenics, injecting momentum into the companies' 2022 collaboration. …

MacroGenics (MGNX) gains $86M on CDMO sale as royalties and milestones rise

MacroGenics reported a Q2 2026 profit driven by an $86.1 million gain from the sale of its CDMO operations for approximately $119.6 million. The company's total revenue significantly increased to $32.8 million due to a $24.5 million milestone from Sanofi and higher ZYNYZ royalty …

Armistice Capital (MGNX) discloses 5.0M-share MacroGenics position in 13G/A

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 5,006,752 shares of MacroGenics, Inc. common stock, which represents 7.88% of the outstanding class. Both Armistice Capital, as investment manager, and Steven Boyd, as its managing member, hold shared voting and dispositive …

HC Wainwright Has Bullish Estimate for ACRV FY2030 Earnings

Pasupati Acrylon FY26 Results: Net profit up 98% to ₹699 crore

MacroGenics (NASDAQ:MGNX) Posts Earnings Results, Beats Estimates By $0.39 EPS

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

MacroGenics Inc earnings missed by $1.02, revenue fell short of estimates

MacroGenics Inc (NASDAQ: MGNX) reported second-quarter earnings per share (EPS) of $-1.10, missing analyst estimates by $1.02, and revenue of $32.83M, which fell short of the consensus estimate of $59.14M. The company's stock has seen significant volatility, being down 4.00% in the last three …

MacroGenics Q2 EPS $(0.31) misses estimate; revenue falls short

MacroGenics (NASDAQ: MGNX) reported a Q2 2026 adjusted EPS of $(0.27), significantly missing the $(0.13) estimate, and revenue of $32.832 million, falling short of the $67.456 million forecast despite a 47.62% YoY increase. The company posted a net income of $19.5 million, a turnaround …

MacroGenics : Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner

MacroGenics reported its second quarter 2026 financial results, highlighting a significant corporate restructuring including the sale of its manufacturing operations for $122.5 million. This transition to a fully outsourced model has streamlined the company, reducing its workforce to approximately 140 people to focus on …

MacroGenics GAAP EPS of -$1.10 misses by $1.02, revenue of $32.83M misses by $26.31M

* MacroGenics press release [https://seekingalpha.com/pr/20619132-macrogenics-reports-second-quarter-2026-financial-results-streamlined-operating-model-and] (MGNX [https://seekingalpha.com/symbol/MGNX]): Q2 GAAP EPS of -$1.10 misses by $1.02. * Revenue of $32.83M (+377.9% Y/Y) misses by $26.31M. MORE ON MACROGENICS * MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important [https://seekingalpha.com/article/4925873-macrogenics-whipsaws-on-clinical-data-but-the-big-picture-is-still-important] * MacroGenics: 'Hold' …

Piper Sandler Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $8

Piper Sandler has reiterated its Buy rating on Acrivon Therapeutics (ACRV.US) and maintained its price target at $8. This indicates continued confidence from the firm in the company's financial prospects and stock performance.

Sands Capital group (NASDAQ: ACRV) discloses 5.3% Acrivon ownership in 13G/A

Sands Capital Life Sciences Pulse Fund II, L.P. and its affiliated entities have disclosed a beneficial ownership of 5.3% in Acrivon Therapeutics, Inc. (NASDAQ: ACRV), totaling 2,289,271 shares. This information was reported in a Schedule 13G/A filing with the SEC, based on 42,853,362 shares …

MacroGenics: Q2 Earnings Snapshot

MacroGenics Inc. (MGNX) reported second-quarter earnings of $19.5 million, or 31 cents per share, significantly exceeding Wall Street's expectation of a 40-cent loss per share. However, the biopharmaceutical company's revenue of $32.8 million fell short of the $44 million forecast by analysts. The earnings …

Are Investors Undervaluing Macro Bank (BMA) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, value …

BH Macro Limited - Transaction in Own Shares

MacroGenics, Inc. $MGNX Shares Bought by Wasatch Advisors LP

Wasatch Advisors LP significantly increased its stake in MacroGenics (NASDAQ:MGNX) during the second quarter, purchasing an additional 459,180 shares to bring its total ownership to over 2 million shares, valued at approximately $9.3 million. This increase means Wasatch Advisors now owns 3.18% of the …

Pasupati Acrylon Q1 profit jumps to ₹27.4 crore; AGM on Sep 9

SKYX Platforms Corp (SKYX) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ...

This article first appeared on GuruFocus. Release Date: August 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Record Q2 2026 revenue of $25.3 million, up 14% sequentially and 10% year-over-year, marking 10 …

Acrivon Therapeutics Q2 Results: EPS beats estimate, losses narrow 22% YoY

Acrivon Therapeutics reported a Q2 2026 net loss of $18.0 million, which translates to $(0.43) per share, significantly beating analyst estimates by 14% and narrowing losses by 21.82% year-over-year. The improved financial performance was attributed to reduced R&D and G&A expenses. The company holds …

Acrivon Therapeutics (NASDAQ:ACRV) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Acrivon Therapeutics (NASDAQ:ACRV) reported its quarterly earnings, posting a loss of $0.43 per share, which beat analyst expectations by $0.06. Despite this, shares declined by 0.6% to $1.72 during midday trading. The company maintains a "Moderate Buy" consensus rating from analysts, with an average …

Acrivon Therapeutics GAAP EPS of -$0.43 beats by $0.07

* Acrivon Therapeutics press release [https://seekingalpha.com/pr/20617353-acrivon-reports-second-quarter-2026-financial-results-and-highlights-upcoming-2026-clinical] (ACRV [https://seekingalpha.com/symbol/ACRV]): Q2 GAAP EPS of -$0.43 beats by $0.07. * As of June 30, 2026, the company had cash, cash equivalents and investments of $90.0 million, which is expected to fund operating expenses and capital expenditure requirements …

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Acrivon Therapeutics announced its second-quarter 2026 financial results, reporting a net loss of $18.0 million and $90.0 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q4 2027. The company highlighted upcoming clinical data catalysts for ACR-368, including a Phase …

Acrivon Therapeutics Inc (ACRV) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Acrivon Therapeutics Inc (ACRV), including analyst ratings, price targets, and expected EPS and revenue figures. Based on ratings from 8 analysts, the stock has a "Buy" trend with a target price of USD 11.50, representing a potential …

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

MacroGenics, Inc. announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program, triggering a $10 million payment to MacroGenics. This program incorporates MacroGenics’ TRIDENT® platform and targets solid tumors. MacroGenics remains eligible for up to …

A Look at Banco Macro SA (BMA) After 4.5% Decline -- GF Value $3

MacroGenics stock rises on $10M Gilead option exercise By Investing.com

MacroGenics Inc. shares rose 4.3% after Gilead Sciences exercised its option on a preclinical bispecific program, resulting in a $10 million payment to MacroGenics. This exercise is part of a 2022 collaboration agreement, under which MacroGenics could receive up to $1.6 billion in additional …

BH Macro Limited (BHMG) Repurchases 7,500 US Dollar Shares at $4.28 Each, Adds to Treasury Stock

Santacruz Silver Mining Ltd. Revenue Breakdown – LSX:A41S50

Santacruz Silver Mining Ltd. (LSX:A41S50) generated €277.89 million in revenue last year. The Zimapan segment was the top-performing segment, contributing €88.75 million, an increase from €75.12 million the previous year. Geographically, Bolivia was the largest contributor to revenue, accounting for €194.01 million.

MacroGenics Inc expected to post a loss of 13 cents a share - Earnings Preview

MacroGenics Inc is projected to report a loss of 13 cents per share. This information is part of an earnings preview, indicating an upcoming financial announcement from the company. The full article is available through a subscription to TradingView.